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Purpose: To identify variables predictive of the need for future vascular intervention in 
a leg contralateral to one currently undergoing infrainguinal bypass. 
Methods: We reviewed the records of 450 consecutively treated patients undergoing 
infrainguinal bypass for occlusive disease to examine the outcome of a previously 
untreated contralateral leg. Patients with coexistent contralateral limb-threatening 
ischemia t the time of initial ipsilateral operation were excluded, as were patients with 
bilateral disease who underwent a staged contralateral procedure within 3 months of the 
ipsilateral operation. This yielded a study cohort of 383 patients with no anticipated 
intervention i  the contralateral leg who were followed for a mean value of 38 months. 
Patient survival and subsequent intervention i the contralateral leg were examined with 
life-table and regression analysis. 
Results: Mean age of the patients was 68 years; 60% were men; 54% had diabetes; and 
50% had coronary artery disease. The initial ipsilateral operation was performed for limb 
threat in 90% of instances. Twenty percent of patients ubsequently needed intervention 
in the contralateral leg (infrainguinal bypass 83%, primary major amputation 17%). 
According to life-table analysis, 30% of patients needed intervention at 5 years, and the 
overall survival rate was 51% at 5 years. Multivariate analysis indicated that the need for 
future contralateral intervention was independently predicted with the following four 
risk factors: diabetes (relative risk [RR] 2.4×), coronary artery disease (RR 1.8×), lower 
initial ankle-brachial index (RR 2.1× with ankle-brachial index less than 0.7), and 
younger age (RR 2.2× if age less than 70 years). Regression models predicted the need 
for contralateral intervention for only 8% of patients at 5 years when none of these risk 
factors was present but for 67% when all risk factors were present. 
Conclusion: The fate of the contralateral leg after infrainguinal bypass is affected by dia- 
betes, coronary artery disease, contralateral nkle-brachial index, and age at initial ipsilater- 
al bypass. The effect of these risk factors is additive in prediction of the likelihood of future 
intervention. Knowledge of these factors may help identify instances in which the con- 
tralateral greater saphenous vein will be important for future limb salvage and also deter- 
mine which patients need more careful follow-up care. (J Vasc Surg 1998;27:1039-48.) 
As many as 25% of  patients who undergo 
infrainguinal bypass subsequently need revascular- 
ization of  the contralateral extremity.i, 2 However, 
predicting which patients with only mild symptoms 
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in the contralateral leg will need intervention in 
that leg remains difficult. Such knowledge could 
improve decision making regarding early use of  
saphenous vein from this leg for coronary bypass or 
leg bypass when ipsilateral vein is inadequate. Simi- 
larly, better understanding of the natural history of 
the contralateral leg might alter the frequency of  
follow-up examinations and the duration of  the fol- 
low-up period and improve patient counseling with 
regard to foot care and risk-factor modification. We 
reviewcd the cases of  patients undergoing infrain- 
guinal bypass to better delineate the natural history 
of the contralateral lower extremity and to identify 
specific variables predictive of future intervention in 
that leg. 
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METHODS 
All patients who underwent infrainguinal arterial 
bypass for occlusive disease at the Dartmouth- 
Hitchcock Medical Center from January 1, 1987, to 
August 31, 1996, were found through a prospective 
computer egistry. Patients who underwent opera- 
tions for trauma, aneurysmal disease, or vasculitis 
were excluded, as were patients with a history of 
infrainguinal revascularization r major amputation 
of the contralateral extremity. Finally, patients who 
underwent vascular intervention i  the contralateral 
lower extremity within 3 months of the initial revas- 
cularizarion of the ipsilateral leg were excluded to 
ensure that the study cohort consisted only of 
patients who had no indication for revascularization 
of the contralateral leg and no history of contralat- 
eral therapy for vascular insufficiency at the time of 
initial presentation. 
Data collected in this study included age, sex, 
presence of diabetes, coronary artery disease (CAD, 
defined as previous myocardial infarction, coronary 
artery bypass operation, percutaneous transluminal 
coronary angioplasty, or angina under treatment), 
renal function (defined as normal [creatinine <2.0 
mg/dl] ,  insufficient [creatinine _>2.0 mg/dl] ,  or 
dialysis dependent), smolcing history (at least 20 
pack years), hypertension (categorized as current 
systolic blood pressure >160 mm Hg, diastolic 
blood pressure >90 mm Hg, or antihypertensive 
treatment), and history of stroke. Data regarding 
the bypass in the ipsilateral leg included indications 
(stratified as claudication, rest pain, or tissue loss) 
and distal target artery (above-knee popliteal, 
below-knee popliteal, tibial or pedal). 
Data regarding the contralateral leg at initial ipsi- 
lateral operation included symptoms, evidence of 
tissue loss or ulcer, ankle brachial index (ABI), and 
arterial Doppler wave forms at the ankle. To correct 
for calcified vessels, an ABI >0.90 associated with 
only monophasic wave forms was considered falsely 
elevated, and these values were excluded from ABI 
calculations. Similarly, an ABI _>1.3 but with good 
biphasic or normal triphasic wave forms was assigned 
a value of 1.3, to correct for reduced upper extremi- 
ty pressure. (Subsequent data analysis was performed 
both with and without these ABI corrections). Sur- 
vival, death, and incidence of subsequent vascular 
intervention (revascularization, major amputation, or 
angioplasty) in the contralateral extremity were con- 
firmed through medical records or telephone contact 
with patients or family members. 
Intervention rates in the contralateral extremity, 
patient survival rate, and intervention-free survival 
rate were analyzed by means of life-table methods. 
(All survival curves are shown only to the time when 
the standard error was less than 10%). Intervention 
rate considered contralateral intervention as the only 
end point, and intervention-free survival rate con- 
sidered either contralateral intervention or death as 
an end point. Differences in life-table outcomes 
were compared by means of the Mantel-Hacnszcl 
log-ranl¢ test. A Student test was used to compare 
continuous variables between groups, and a chi- 
square test was used for categorical variables. Multi- 
variate logistic regression analysis with Cox propor- 
tional hazards model was used to assess the influence 
of risk factors on the need for subsequent contralat- 
eral intervention and patient survival. Potential pre- 
diction variables, including age, sex, presence of dia- 
betes, CAD, hypertension, smoking, or stroke, renal 
function, indications for initial operation, initial tar- 
get vessel, and contralateral ABI were entered into 
the regression equation in a stepwise manner if p < 
0.10 and considered significant in the final regres- 
sion equation ifp < 0.05. Regression coefficients for 
the significant variables from the Cox model were 
then used to predict risk for future contralateral 
intervention for combinations of these risk factors. 
From January 1, 1987, to August 31, 1996, 526 
patients underwent infrainguinal bypass for occlu- 
sive disease. Of these, 15 (2.8%) had incomplete or 
lost records and were excluded from analysis. Fifty- 
nine patients (11%) were excluded because they had 
undergone prior revascularization (37 patients) or 
major amputation (22 patients) of the contralateral 
extremity at the time of initial presentation for ipsi- 
lateral operation at our institution. One patient with 
congenital absence of the contralateral extremity and 
one patient with Buerger's disease were excluded. 
To ensure a focus on patients with an uncertain at- 
ural history in the contralateral leg at the time of ini- 
tial ipsilateral operation, patients with coexistent 
limb-threatening ischemia (rest pain [20 patients, 
4%] or tissue loss [39 patients, 7%]) in the contralat- 
eral extremity at the time of the initial ipsilateral 
operation also were excluded, as were patients with 
clandication (8 patients, 2%) with bilateral disease 
who underwent staged procedures within 3 months 
of the initial operation. These exclusions yielded a 
primary study cohort of 383 patients who under- 
went infrainguinal bypass of one lower extremity and 
had no history of or anticipated intervention i  the 
contralateral lower extremity at the time of the ini- 
tial operation. Complete follow-up information was 
available on 94% of these patients for a mean inter- 
val of 38 +- 30 (SD) months. 
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Fig. 1. Rate of intervention i  the contralateral extremity after infrainguinal bypass mong 383 
patients. 
RESULTS 
The study group had a mean age of 68 _+ 11 years 
(SD, range 33 to 95 years); 60% were men; 54% had 
diabetes, and 50% had CAD. Eighty-nine percent 
had normal renal function; 7% had renal insufficien- 
cy, and 4% were dependent on dialysis. Seventy-one 
percent had hypertension; 62% had smoked at least 
20 pack years; and 16% had a previous troke. Indi- 
cation for initial ipsilateral revascularization was limb 
threat in 90% of instances (tissue loss 60%, rest pain 
30%, claudication 10%), with the initial ipsilateral 
target artery at the tibial-pedal level in 65% of 
instances. At the time of initial ipsilateral revascular- 
ization, 73% of patients had no symptoms in the 
contralateral extremity, and 27% had clandication. 
After ipsilateral infrainguinal bypass 77 (20%) of 
the 383 patients needed intervention in the con- 
tralateral extremity after a mean interval of 31 + 24 
(SD) months. According to life-table analysis, the 
rate of contralateral intervention was 13% at 2 years 
and 30% at 5 years after the initial ipsilateral leg 
bypass. This intervention rate was relatively linear at 
6% per year (Fig. 1). Intervention consisted of 
infrainguinal bypass for 64 patients (83%) and prima- 
ry major amputation for 13 patients (17%). Percuta- 
neous balloon angioplasty was not performed on any 
of the contralateral legs because of advanced isease 
at the time of intcrvention. Indication for contralat- 
eral bypass was fimb salvage in 86% of instances (40 
patients with tissue loss, 15 with rest pain) and dis- 
abling daudication in 14%. Of the 13 patients who 
underwent primary amputation, 7 were treated else- 
where. Six were treated at our institution and judged 
unsuitable for revascularization, i  part because of 
absence of suitable venous conduit in that extremity, 
most often because of previous coronary revascular- 
ization. Other reasons for primary amputation 
included combinations of medical comorbidity, 
extensive tissue loss, and severe infection. 
The patient survival rate after the initial bypass 
was 76% at 2 years and 51% at 5 years (Fig. 2). Sur- 
vival rate free of intervention i the contralateral leg 
was 68% at 2 years and 37% at 5 years (Fig. 2). In the 
subgroup of 77 patients who needed contralateral 
leg intervention, survival after their second proce- 
dure was 64% at 2 years and 33% at 5 years. 
Patients who needed subsequent intervention 
in the contralateral extremity were younger than 
those who did not need such intervention (mean 
value + SD 65 -+ 10 vs 69 +_ 11 years, p < 0.05), more 
frequently had diabetes (69% vs 50%, p < 0.001), 
more often had CAD (61% vs 48%, p < 0.01), and 
had a lower ABI in the contralateral leg (mean value 
-+ SD 0.65 + 0.20 vs 0.76 _+ 0.27, p < 0.05) at the 
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Fig. 2. Overall rates of survival and survival free of contralateral intervention after infrain- 
guinal bypass. 
Table I. Five-year intervention and survival rates 
for significant risk factors 
5-year 5-year 
Risk factor intervention rate (%) survival rate (%) 
All patients 30 + 3 51 ± 3 
Age 
>70 years 21 40 
<70 years 38 64 
Diabetes 
No 18 58 
Yes 43 44 
Coronary artery disease 
No 22 56 
Yes 38 44 
Anlde-brachial index 
>0.7 26 55 
<0.7 35 48 
timc of initial ipsilateral operation (Table I). The fre- 
quency and distribution of other risk factors, includ- 
ing renal disease, smoking history, hypertension, and 
history of stroke were not significantly different 
between patients who needed future intervention in 
the contralateral leg and those who did not (Table 
II). Indications for initial ipsilateral operation, target 
vessel for initial ipsilateral operation, and symptoms 
in the contralateral leg at the time of initial operation 
also were not predictive of future intervention in the 
contralateral extremity (Table II). 
The mean interval from initial ipsilateral opera- 
tion to contralateral intervention ranged from 4 to 
I04 months with a mean value of 3i ± 24 (SD) 
months. In this subgroup of patients requiring con- 
tralateral intervention, those with CAD needed 
intervention sooner than those without CAD (27 vs 
38 months, p < 0.05). Time to contralateral inter- 
vention among patients with diabetes was less than 
that among patients without diabetes (30 vs 34 
months, p = 0.051). Interval to intervention was not 
effected by age or ABI. 
One hundred sixty-seven patients (44%) died dur- 
ing the follow-up period (Fig. 2). According to uni- 
variate analysis, diabetes, CAD, lower ABI, dialysis- 
dependent renal failure, and advanced age were asso- 
ciated with lower survival rates (all p < 0.05). 
According to multivariate analysis, diabetes, lower 
ABI, dialysis-dependent renal failure, and advanced 
JOURNAL OF VASCULAR SURGERY 
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Table II. Demographic data 
Characteristic 
l'aHenu without 
subsequent 
intervenNon 
Patients with 
subsequent 
intervention p Value 
Total 306 (80) 
Age (yr; mean + SD) 69 + 11 
Male 180 (59) 
Diabetes 154 (50) 
Coronary artery disease 146 (48) 
Renal function 
Normal 273 (89) 
Chronic renal insufficiency 19 (6.2) 
(creatinine >2.0 mg/dl) 
Dialysis dependent 14 (4.6) 
Smoker (>20 pack years) 189 (62) 
Hypertension 215 (70) 
History of stroke 48 (16) 
Indication for initial operation 
Claudication 26 (8) 
Rest pain 103 (34) 
Tissue loss 177 (58) 
Initial ipsilateral target 
Above knee popliteal 47 (15) 
Below knee popliteal 60 (20) 
Tibial-pedal 199 (65) 
Symptoms in contralateral leg 
at time of initial ipsilateral 
operation 
None 229 (75) 
Claudication 77 (25) 
Ank/e-brachial index in 0.76 _+ 0.27 
contralateral leg at time of 
initial revascularization 
(mean value +_ SD) 
77 (20) 
65 + 10 
49 (64) 
53 (69) 
47 (61) 
68 (88) 
6 (7.8) 
3 (3.9) 
47 (61) 
58 (75) 
15 (20) 
11 (14) 
15 (20) 
51 (66) 
12 (16) 
17 (22) 
48 (62) 
51 (66) 
26 (34) 
0.65 _+ 0.20 
<0.05 
NS 
<0.001 
<0.01 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
<0.05 
Unless otherwise indicated, values are number of patients with percentage in parentheses. 
NS, not significant. 
age were independent predictors of a lower survival 
rate (Table III). 
According to multivariate analysis, diabetes (p < 
0.001), CAD (p < 0.01), lower ABI (p < 0.05), and 
younger age (p < 0.05) were independent predictors 
of the need for future intervention i  the contralat- 
eral extremity (Table IV). A Cox proportional haz- 
ards model (stratifying ABI as <0.7 or >0.7 and age 
as <70 or >70 years) was used to evaluate the pre- 
dicted effect of these risk factors and combinations 
thereof on the natural history of the contralateral leg 
(Table V). The resulting regression equation was as 
follows: Probability (intervention) = 1 - S0(t)exP 
[(0.69 if diabetes) + (0.64 if CAD) + (-0.76 ifABI <0.7)+ (-0.80 if 
age <70)], where S0(t ) = the baseline probability of in- 
tervention [S0(t ) = 0.897 at 2 years and 0.746 at 
5 years], To further determine the effect of variation 
in absolute age and ABI, a second Cox model (with 
age and ABI as continuous variables) was used, and 
the resulting regression equation was as follows: 
Probability (intervention) = 1 - S0(t)exp[( 0"26 if dia- 
betes) + (0.58 if CAD) + (-0.39 x age) + (-0.58 x ABI]), where 
S0(t ) = 0.096 at 2 years and 6.79 × 10 -4 at 5 years. 
As shown in Fig. 3 and Table V, these risk factors 
were additive in predicting the need for future inter- 
vention in the contralateral leg. The Cox model pre- 
dicted that only 6% of patients with none of these 
risk factors would need surgical treatment, whereas 
67% of patients with all four risk factors would need 
intervention within 5 years after the initial, ipsilater- 
al bypass. Predicted intervention rates varied in pro- 
portion to initial ABI and age as continuous vari- 
ables. For example, for a 70-year-old patient with 
diabetes and CAD, the predicted 5-year need for 
contralateral intervention increased from 39% to 
62% as initial ABI decreased from 0.8 to 0.4. Simi- 
larly, for a patient with diabetes, CAD, and an initial 
ABI of 0.7, the 5-year predicted contralateral inter- 
vention requirement varied from 33% to 72% as age 
decreased from 80 to 50 years. 
DISCUSSION 
Despite the importance of the contralateral 
extremity in the long-term outcome for patients 
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Fig. 3. Predicted rates of contralateral intervention among patients with combinations f sig- 
nificant risk factors according to Cox proportional hazards model. 
with ipsilateral peripheral vascular disease, the fate of 
the leg contralateral compared with the one under- 
going revascularization has not been well defined. A 
better understanding of the natural history of the 
contralateral extremity might alter both immediate 
and future plans for a patient. For example, surgeons 
undertaking lower-extremity revascularization 
encounter patients without suitable ipsilateral 
greater saphenous vein in as many as 45% of 
instances. 3-~ Although some groups routinely use 
greater saphenous vein from the contralateral 
extremity, other surgeons are reluctant o harvest 
vein from the opposite leg, believing the patient has 
a high likelihood of needing coronary or contralat- 
eral lower extremity bypass at some future time.l,2, 6
Unfortunately, few factors that can be used for accu- 
rate prediction of which patients are likely to need 
future intervention in the contralateral lower 
extremity have been described. We identified specif- 
ic risk factors available at the time of initial infrain- 
guinal revascularization (diabetes, CAD, ABI, and 
age) that helped predict the need for future inter- 
vention in the contralateral leg. 
Diabetes. Diabetes occurred among 54% of our 
patients and was the best predictor of future inter- 
vention in the contrallateral lower extremity (Table 
IV), increasing the relativc risk 2.4 times. Although 
diabetes is known to accelerate peripheral arterial 
disease, it also reduces urvival rate, so the net effect 
on future intervention requirement has previously 
not been obvious. Kalman et al.7 reviewed the cases 
of a series of 358 patients undergoing infrainguinal 
bypass and found that patients with diabetes had a 5- 
year survival rate of only 33% compared with 54% for 
patients without diabetes. In our study, we found a 
similarly diminished survival rate of 44% at 5 years 
for patients with diabetes compared with 58% for 
patients without diabetes. Such poor survival rates 
might appear to preclude the need for future revas- 
cularization in a limb with minimal or no symptoms 
at ipsilateral presentation, simply because patients 
with diabetes are unlikely to live long enough to 
develop limb-threatening ischemia. However, accel- 
erated atherosclerosis  very significant among 
patients with diabetes, who tend to have multiple 
risk factors. We found a 43% contralateral interven- 
tion requirement within 5 years of ipsilateral bypass. 
We believe that this high likelihood of intervention 
should discourage use of the contralateral saphenous 
vein at the time of initial limb salvage operations on 
patients with diabetes. Rapid progression of periph- 
eral arterial disease among patients with diabetes 
JOURNAL OF VASCULAR SURGERY 
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Table II I .  Independent predictors of overall survival 
Variable Regression coefficient Relative risk 95% Confidence interval p Value 
Dialysis 1.8 6.0 2.9-12 <0.001 
Age 270 yr 0.86 2.3 1.6-3.3 <0.001 
Diabetes 6.5 1.9 1.4-2.7 <0.001 
Anlde-brachial index <0.7 0.39 1.5 1.1-2.1 <0.05 
also is an argument for more frequent follow-up 
examinations with particular attention to preventive 
care and close surveillance of the contralateral leg. 
Coronary  artery disease. Numerous studies 
have documented that CAD is closely associated 
with lower-extremity atherosclerosis, accounting for 
as many as 60% of deaths after leg bypass. 8-11 Thus 
it is not surprising to find that overt CAD is a sig- 
nificant marker for more diffuse or progressive 
peripheral atherosclerosis, as we found in this study. 
Patients in our study with CAD carried a 1.8 times 
greater isk for requiring future contralateral inter- 
vention. According to our Cox regression model, 
11% of patients with CAD alone, in the absence of 
the other three risk factors, were predicted to need 
intervention after 5 years, compared with only 6% of 
patients without CAD. Among selected patients 
with only CAD and diabetes, more than 20% were 
expected to need contralateral operations within 5 
years. We believe that this may be the first docu- 
mentation that the presence of CAD appears to bc 
an independent predictor of the need for arterial 
intervention i  a previously untreated and relatively 
symptom-frec lcg. Thus as with diabetes, thc 
increased need for future contralateral intervention 
among patients with CAD urges caution in the use 
of the contralateral greater saphenous vein for ipsi- 
lateral eg bypass. 
Ankle-brachial index. Our finding that a lower 
ABI in the contralateral extremity at the time of initial 
ipsilateral bypass is predictive of future need for inter- 
vention is consistent with previous reports concerning 
the progression of peripheral vascular disease. 12-14 
There was sufficicnt overlap in mcan ABI values for 
patients who did and did not need future interven- 
tion, however, that no accurate spccific threshold for 
clinical decision-making using absolute ABI is possi- 
ble. Given the high prevalence of diabetes among our 
patient population, it is possiblc that incompressible 
arteries and falsely elevated ABIs confounded our 
analysis. We attempted to address this by analyzing 
real ABI values as well as those corrected for poten- 
tially inaccurate readings, but this did not change our 
conclusions. It is possible that toe pressure or toe- 
Table IV. Independent predictors of future inter- 
vention in the contralateral extremity 
95% 
Regression Relative Confidence 
Variable coefficient risk interval p Value 
Diabetes 0.86 2.4 1.4-3.9 <0.001 
Coronary 
artery disease 0.58 1.8 1.1-2.9 <0.01 
Ankle-brachial 
index <0.7 0.76 2.1 1.3-3.6 <0.05 
Age <70 yr 0.80 2.2 1.3-3.8 <0.05 
brachial index might be a more accttrate predictor of 
future intervention. Similarly, ABI after exercise test- 
ing or hyperemia might also aid in predicting subse- 
quent need for contralateral intervention but was not 
routinely performed in our patients. Nonetheless, in
the context of other risk factors, a lower ABI might 
indeed alter treatment plans. For example, of all the 
patients in our cohort with an initial ABI <0.7, 35% 
needed contralateral intervention after 5 years com- 
pared with 25% of those with an initial ABI >0.7. 
Age. Younger patients in our study group were 
significantly more likely to need future intervention i
their contralateral lower extremity than were older 
patients. This is likely the result of a combination of 
longer survival among younger patients as well as 
more aggressive atherosclerosis. Younger patients in 
our series did indeed live longer with a 5-year survival 
rate of 64% among patients younger than 70 years 
compared with 40% among patients 70 years or older. 
However, when analyzed with life-table methods 
independent of survival, contralateral intervention 
rates were still higher among younger patients with 
38% of patients younger than 70 years needing opera- 
tions at 5 years compared with 21% of those 70 years 
or older. Furthermore, the mean interval from initial 
operation to contralateral intervention was not differ- 
ent between these age groups. This suggests hat 
younger patients are not simply living longer to under- 
go more interventions, but they have more aggressive 
atherosclerosis, a  has been suggested previously. 15-17 
Our Cox model also suggested that youth has an 
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Table V. Predicted contralateral intervention rates based on different combinations of risk factors accord- 
ing to Cox proportional hazards model 
Risk factor Intervention rate (%) 
Coronary artery Ankle-brachial 
Diabetes disease index < O. 7 Age < 70 yr 2 year 5 year 
. . . .  2 6 
- + - - 4 11 
+ - - - 4 12  
- - + - 5 12 
- - - + 5 13 
+ + - - 8 21  
- + + - 9 21 
- - + + 10 25  
+ - - + 10  25  
+ + + - 17  39  
- + + + 19 43  
+ + + + 33  67  
-, factor absent; +, factor present. 
additive effect even in the presence of other promi- 
nent risk factors such as diabetes. The predicted 5- 
year intervention rate among patients with diabetes 
alone is 12%, whereas our model predicted a 25% 5- 
year intervention rate among "young" patients with 
diabetes with no other significant risk factors (Table 
V). An analysis of underlying causes of this effect of 
age on contralateral intervention was beyond the 
scope of our study, but it likely includes a combina- 
tion of higher rates of smoking, hyperlipidemia, nd 
hypercoagulable states among younger patientsjS, 17 
CONCLUSION 
The results of our regression analysis hould facili- 
tate the sometimes difficult selection of a conduit for 
infrainguinal bypass in the absence of adequate vein in 
the ipsilateral lower extremity. Among patients with 
severe lower extremity atherosclerosis who have no 
evidence of diabetes or CAD, and no significant arter- 
ial symptoms in the contralateral leg, the likelihood of 
future contralateral intervention is less than 10% dur- 
ing the next 5 years. Thus one could use contralateral 
greater saphenous vein as a bypass conduit confident 
that the need for revascularization i the donor leg is 
unlikely. Unfortunately, in our typical population of 
patients who needed infrainguinal revascularization, 
only 8% of patients fulfilled these requirements and 
had none of these risk factors. Rather, 32% of the 
patients in our study had both diabetes and CAD and 
31% of these patients needed intervention i the con- 
tralateral leg within 5 years of initial infrainguinal 
revascularization. Furthermore, 22% of our patients 
had diabetes, CAD, and low initial ABI, and half of 
these patients needed later contralateral intervention. 
Some groups advocate using the "optimal" vein 
(the contralateral greater saphenous vein) if neces- 
sary for revascularization in the ipsilateral leg rather 
than "saving" it for future use. However, our data 
might dissuade one from this approach. First, 
because contralateral intervention is so frequent 
among patients with multiple risk factors, use of vein 
from the contralateral leg today may only delay the 
decision to find an alternative conduit. Second, the 
specific anatomic determinants for conduit length 
needed for bypass of the immediately affected ipsi- 
lateral leg are clear, whereas the future anatomic 
requirements for bypass conduit length of the con- 
tralateral leg are unknown. In other words, the ipsi- 
lateral leg may be amenable to arm vein bypass 
today, whereas the contralateral leg may well need 
longer or more "refiable" greater saphenous vein in 
the future. 
We believe that selection of a bypass conduit for 
infragenicular lower-extremity revascularization in 
the absence of ipsilateral greater saphenous vein is 
complex. For older patients whose only risk factor is 
unilateral advanced athcrosclerosis, contralateral 
greater saphenous vein is the conduit of choice. For 
a younger patient with diffuse atherosclerosis, par- 
ticularly in the presence of diabetes, careful assess- 
ment of required bypass length, arm vein quality, 
with the aforedefined risk groups often will lead to 
preferential use of arm vein for the initial, ipsilateral 
bypass. The concept hat these patients' poor long- 
term survival will preclude need for use of the con- 
tralateral saphenous vein as a bypass conduit for car- 
diac or contralateral lower-extremity revasculariza- 
tion should be questioned. 
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DISCUSSION 
Dr. Anthony Whittemore (Boston, Mass.). I am fasci- 
nated by the fact that the risk factors are additive, and I 
think that you have put together a useful set of observa- 
tions. Unless I missed something, though, you did not 
look at all conceivable permutations. For instance, you did 
not look at age and diabetes together. 
I am curious why you think that the younger age 
group is at a higher risk. Is it because the older group 
more frequently dies before their graft fails, or is it because 
that group has a higher incidence of diabetes? 
Dr. Wallace C. Tarry. With regards to different com- 
binations of risk factors, we showed the overall risk for just 
a few of the combinations of risk factors. If one examines 
all the permutations f risk factors in our Cox model, they 
are indeed additive and fall into a sequential pattern as you 
might predict. 
With regards to age, we wrestled with these same 
questions. However, when we examined intervention rates 
in the contralateral extremity independent of survival, we 
found that younger patients still had a higher likelihood of 
needing contralateral intervention. We believe, as previ- 
ously written, that younger patients have more aggressive 
athcrosclcrosis. The underlying cause for this is likely mul- 
tifactorial, and I could only speculate on the excess risk 
factors in this population. 
Dr. Robert W. Hopkins (Providence, ILI.). One risk 
factor that might have been changeable in these patients 
was smoking. Were you persuasive enough that a signifi- 
cant number of patients topped smoking? If so, were 
there enough patients who quit smoking to compare with 
those who did not quit? Was there a difference? 
Dr. Tarry. I have a few things to mention with regards 
to smoking. First, I did not show this in the paper, but 
there was no difference in the rate of tobacco use between 
patients who required subsequent contralateral interven- 
tion and those who did not. Second, I think that we are all 
frustrated that our success in actually having patients quit 
smoking is fairly limited. So, in this retrospective analysis, 
we were unable to determine xactly who had truly quit 
and for how long. Therefore, I cannot address the effects 
of smoking cessation. 
Dr. James M. Estes (Boston, Mass.). I wonder if you 
examined more closely the relationship between ankle 
brachial index and the need for intervention on the con- 
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tralateral leg. I think that the cutoff that you selected for 
0.7 seems on the high side for patients who are being oper- 
ated predominantly for limb salvage. I am wondering what 
the results were for ankle brachial indices at 0.4 or 0.5. 
Dr. Tarry. I first emphasize that the ankle brachial index 
that I showed refers to the contralateral, relatively asymp- 
tomatic leg at the tiffle of the first operation. Because we 
excluded patients with rest pain and tissue loss in the con- 
tralateral leg at the time of initial surgery, one might expect 
this to be somewhat higher. Nonetheless, when we exam- 
ined ankle brachial index as a continuous variable in our 
Cox model, lower indices did indeed proportionally 
increase risk as you would expect. We chose the value of 
0.7 as a rough clinical cutoff or as a number that most of 
us would carry as a basic clinical correlate. Overall, you are 
exactly right, the lower ankle brachial indices, such as 0.4 
or 0.5, increased the risk of future intervention. 
Dr. Bruce Cutler (Worcester, Mass.). The risk factors 
that you mention are, of course, also risk factors for coro- 
nary artery disease. The conclusion of your paper states 
that one might wish to preserve the contralateral vein if 
multiple risk factors were present. Did you consider the 
future need for coronary artery bypass surgery to be a 
"risk factor"? If not, is this another and potentially even 
more important reason to preserve the contralateral vein? 
Dr. Tarry. You make an excellent point, but unfortu- 
nately I do not have that data. 
John A. Mannick (Boston, Mass.). I do not want to 
take anything away from your study, but another factor 
enters into the judgement of whether or not to take the 
contralateral vein. That factor is the vascular anatomy in 
the two legs by angiogram. Even with all of your risk fac- 
tors pertaining in the contralateral leg, I can imagine that 
you might take that vein anyway if you needed to do a 
bypass graft. For example, the dorsalis pedis on the ipsilat- 
eral leg and a reconstruction to the above knee popliteal 
would suffice at some future date in the other leg. 
Although the factors you have identified will be helpful, I 
suspect hat the vascular anatomy may be equally impor- 
tant in clinically making a decision. Do you have any infor- 
mation about that? 
Dr. Tarry. I do not have that information. Your point 
of how each leg compares at the time of the initial surgery 
is a good point. With the high incidence of diabetes in our 
study, we feel that the patients are often amenable to 
shorter length bypass inflow at the superficial femoral 
artery level or even further down the profunda. Therefore, 
arm vein has become our prefered conduit when greater 
saphenous vein is unavailable. 
Frank W. LoGerfo (Boston, Mass.). We operate on 
patients with a high incidence of diabetes, and for quite a 
few years, our policy has been use the arm vein as the first 
alternative when the ipsilateral saphenous vein is not avail- 
able. This is just on the basis of the presence of diabetes, 
because many of our patients who undergo limb salvage 
procedures with diabetes have coronary artery disease. I 
would say this is probably universal. So, when you get o 
your data, coronary artery disease and diabetes go t geth- 
er. I am not sure how much the state of the contralateral 
leg plays at the initial visit and the ankle brachial index is 
unpredictable in diabetes. I wonder if you can just use that 
single criterion if you are performing a limb salvage pro- 
cedure on a patient with diabetes where the need for the 
use of that vein in the opposite leg or heart comes out to 
better than 60% at 3 years. Can you use only that criteri- 
on, diabetes alone, to say that when the ipsilateral vein is 
not available you should not use contralateral vein but use 
an arm vein or lesser saphenous vessel? 
Dr. Tarry. As you indicate and as we found, diabetes 
was indeed the strongest predictor of the need for future 
intervention. Our practice at Dartmouth is similar to the 
one you described in that the arm vein is the first choice 
with regard to alternative conduit in diabetics. I think that 
would be a valid goal simply to conserve contralatcral vein 
in all diabetic patients. One of the most interesting find- 
ings of our study, which was in some respects unexpected, 
was that even though diabetics do not seem to live long 
they still have a high intervention rate. I think many sur- 
geons look at diabetics and feel that they will not live long 
enough to need a vein in the other leg. However, our 
study showed just the opposite of that. In other words, 
despite their clearly decreased survival, many diabetics will 
still have a frequent need for that vein in the other leg. 
Wil l iam C. Mackey (Boston, Mass.). The one thing 
that is missing here is the result of the use of contralateral 
saphenous vein versus alternative conduits. My strong bias 
is that I would do what will work best for the problem at 
hand without theorizing about potential future problems. 
I did not see in your abstract or your discussion here what 
the outcome is when you use the contralateral saphenous 
vein versus the alternative conduits. 
Dr. Tarry. That is certainly an excellent point, and I 
cannot answer that question directly with regard to fol- 
low-up data and outcome data in this group of patients. As 
everybody knows, the greater saphenous vein is certainly 
the conduit of choice and is clearly superior to the other 
alternative conduits available. However, when faced with a 
patient who has no available ipsilateral greater saphenous 
vein and a high likelihood of requiting future contralater- 
al intervention, you have a "pay me now or pay me later" 
scenario. In other words, if one elects to harvest vein from 
the other leg today, then the same difficulty with finding 
alternative conduit may become an issue at a future date. 
As Dr. Mannick suggested, anatomic issues could aid in 
facilitating this decision. If the immediate leg in jeopardy 
is amenable to arm vein bypass, then we proceed this way 
because the exact future needs of the contralateral leg and 
future availability of arm vein are more unpredictable. 
